Polypeptide Docking Peptides for Uniform ADC Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antibody drug conjugates (ADCs) face limitations due to poor specificity and non-uniform conjugation methods, which restrict their efficacy and therapeutic window in treating diseases like cancer.
Innovation Solution
Development of specific polypeptide sets that form supramolecular structures at precise ratios, allowing for site-specific and efficient targeting of therapeutic agents by forming tetramers with docking peptides, ensuring uniform loading and high stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional conjugation methods are used for ADCs, then the conjugation process is simpler, but the specificity and uniformity of therapeutic agent loading deteriorates
Solution Approach 1:
The conjugation process is divided into distinct functional modules: a targeting biologic component, a payload component, and a docking peptide system. This segmentation allows each component to be optimized independently while achieving uniform conjugation through the specific interaction between docking peptides and their binding partners, resolving the contradiction between precision and complexity.
Solution Approach 2:
Docking peptides serve as intermediary elements that mediate the connection between the biologic and payload. These peptides provide a standardized interface that ensures uniform and specific conjugation, acting as a bridge that simplifies the overall process while maintaining high precision in therapeutic agent loading.
2Reliability
If traditional ADCs are used, then the therapeutic window is limited, but the specificity to target cells deteriorates
Solution Approach 1:
The docking peptide system enables local optimization of the ADC structure, with specific peptide sequences designed to interact with particular targets. This local quality enhancement ensures that the therapeutic effect is concentrated at the target site while minimizing off-target effects, thereby expanding the therapeutic window and reducing harm to normal cells.
Solution Approach 2:
The invention changes key parameters of the ADC including the specificity of peptide-binding interactions and the uniformity of payload loading. By optimizing these parameters through rational peptide design, the system achieves higher target specificity and an expanded therapeutic window, allowing effective treatment with reduced toxicity to normal cells.
3Productivity
If non-uniform conjugation is used, then the manufacturing process is simpler, but the efficacy of the ADC deteriorates
Solution Approach 1:
The docking peptides are pre-designed and pre-characterized to ensure specific and uniform binding. This preliminary action of optimizing the peptide sequence and binding interface before conjugation allows for high productivity while maintaining uniform payload loading, as the standardized interface enables efficient and consistent conjugation across all ADC molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide-based ADCs demonstrate enhanced specificity and efficacy by achieving precise targeting and stable delivery of therapeutic agents to cancer cells, outperforming traditional methods in terms of cytotoxicity and minimizing harm to normal cells.
Implementation Method 1
certain combinations of docking peptides will not form homo-mers, but given a mixture of two types of docking peptides, the peptides will form tetramers that comprise two of each type of docking peptide
Data Source
AI summary
Described herein are methods and compositions related to compositions comprising combinations of V/K-type and V/E-type docking peptides and uses thereof, e.g., to deliver therapeutic agents to treat certain conditions such as cancer, infection, or trauma.